This is therefore a comparing of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) and ARCA biopharma Inc. (NASDAQ:ABIO). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spring Bank Pharmaceuticals Inc.	N/A	0.00	18.89M	-1.37	0.00
ARCA biopharma Inc.	N/A	0.00	10.64M	-0.82	0.00

Demonstrates Spring Bank Pharmaceuticals Inc. and ARCA biopharma Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both companies.

	Net Margins	Return on Equity	Return on Assets
Spring Bank Pharmaceuticals Inc.	0.00%	-47.4%	-34.4%
ARCA biopharma Inc.	0.00%	-112.6%	-97.5%

Liquidity

The Current Ratio of Spring Bank Pharmaceuticals Inc. is 10.7 while its Quick Ratio stands at 10.7. The Current Ratio of rival ARCA biopharma Inc. is 8.6 and its Quick Ratio is has 8.6. Spring Bank Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than ARCA biopharma Inc.

Insider & Institutional Ownership

Roughly 42.9% of Spring Bank Pharmaceuticals Inc. shares are owned by institutional investors while 15% of ARCA biopharma Inc. are owned by institutional investors. About 4% of Spring Bank Pharmaceuticals Inc.’s share are owned by insiders. Comparatively, 1.17% are ARCA biopharma Inc.’s share owned by insiders.

Performance

In this table we show the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Spring Bank Pharmaceuticals Inc.	-9.25%	-13.63%	-19.94%	-26.09%	-19.62%	-24.11%
ARCA biopharma Inc.	-1.2%	-36.25%	-10.08%	-2.02%	-59.24%	-62.26%

For the past year Spring Bank Pharmaceuticals Inc. was less bearish than ARCA biopharma Inc.

Summary

Spring Bank Pharmaceuticals Inc. beats ARCA biopharma Inc. on 4 of the 6 factors.

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that the company designs to target and modulate the activity of specific proteins implicated in various disease states. The companyÂ’s lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops SMNH product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers; and SB 9400, SB 9941, and SB 9946 preclinical product candidates for viral diseases. The company has an agreement with Arrowhead Pharmaceuticals, Inc. to collaborate on the study of the combined use of SB 9200 and small interfering ribonucleic acid product pipeline for the treatment of chronic hepatitis B virus (HBV); and Arbutus Biopharma Corporation to collaborate on the preclinical study of the combined use of SB 9200 and AB-423, a capsid assembly inhibitor for the treatment of chronic HBV. It also has a clinical trial collaboration agreement with Gilead Sciences, Inc. for a clinical study examining the use of SB 9200 co-administered with GileadÂ’s Vemlidy (tenofovir alafenamide) in chronic HBV patients. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.